Clinical Trial

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

Recruiting
View on ClinicalTrials.gov →
Summary
This project proposes to establish a prospective, multicenter, randomized, controlled clinical study to compare the safety and efficacy of Intralesional Rituximab Injection versus Involved Site Radiation Therapy for the treatment of primary ocular adnexal MALT lymphoma. The aim is to provide high-level clinical evidence for the treatment of ocular adnexal MALT lymphoma and to offer patients treatment options that have fewer complications and comparable therapeutic effects.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-12-19; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2024-02-02
Trial Details
NCT Number NCT06190301
Lead Sponsor Zhongshan Ophthalmic Center, Sun Yat-sen University
Conditions Primary Ocular Adnexal MALT Lymphoma
Enrollment 108 participants
Start Date 2023-12-20
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-20